Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Moderna, Inc. stock logo
MRNA
Moderna
$54.36
+2.8%
$51.79
$22.28
$59.55
$21.56B1.059.81 million shs3.13 million shs
Ocugen, Inc. stock logo
OCGN
Ocugen
$1.46
-1.7%
$1.86
$0.64
$2.73
$495.93M2.37.82 million shs2.62 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.96
+0.6%
$27.09
$21.97
$28.75
$147.82B0.3542.54 million shs8.85 million shs
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
$33.76
-0.7%
$35.96
$8.75
$40.65
$2.01B0.79959,466 shs88,280 shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Moderna, Inc. stock logo
MRNA
Moderna
-2.70%+16.55%+3.77%+25.93%+118.06%
Ocugen, Inc. stock logo
OCGN
Ocugen
-1.99%-17.78%-15.91%+4.23%+120.73%
Pfizer Inc. stock logo
PFE
Pfizer
+0.67%-1.99%-4.03%-6.48%+15.89%
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
-0.90%-0.09%-3.63%+8.28%+237.07%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Moderna, Inc. stock logo
MRNA
Moderna
$54.36
+2.8%
$51.79
$22.28
$59.55
$21.56B1.059.81 million shs3.13 million shs
Ocugen, Inc. stock logo
OCGN
Ocugen
$1.46
-1.7%
$1.86
$0.64
$2.73
$495.93M2.37.82 million shs2.62 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.96
+0.6%
$27.09
$21.97
$28.75
$147.82B0.3542.54 million shs8.85 million shs
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
$33.76
-0.7%
$35.96
$8.75
$40.65
$2.01B0.79959,466 shs88,280 shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Moderna, Inc. stock logo
MRNA
Moderna
-2.70%+16.55%+3.77%+25.93%+118.06%
Ocugen, Inc. stock logo
OCGN
Ocugen
-1.99%-17.78%-15.91%+4.23%+120.73%
Pfizer Inc. stock logo
PFE
Pfizer
+0.67%-1.99%-4.03%-6.48%+15.89%
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
-0.90%-0.09%-3.63%+8.28%+237.07%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Moderna, Inc. stock logo
MRNA
Moderna
1.84
Reduce$35.73-34.27% Downside
Ocugen, Inc. stock logo
OCGN
Ocugen
2.60
Moderate Buy$9.75570.10% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.23
Hold$28.7410.71% Upside
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
2.92
Moderate Buy$46.5037.72% Upside

Current Analyst Ratings Breakdown

Latest OCGN, MRNA, PFE, and TYRA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/6/2026
Pfizer Inc. stock logo
PFE
Pfizer
UpgradeHold (C-)Hold (C)
5/4/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetNeutral$36.00 ➝ $45.00
5/4/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetSector Perform$35.00 ➝ $38.00
5/1/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetNeutral$43.00 ➝ $49.00
5/1/2026
Moderna, Inc. stock logo
MRNA
Moderna
Set Price Target$33.00
4/29/2026
Pfizer Inc. stock logo
PFE
Pfizer
Boost Price TargetNeutral$26.00 ➝ $27.00
4/20/2026
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
Reiterated RatingSell (D-)
4/20/2026
Pfizer Inc. stock logo
PFE
Pfizer
Reiterated RatingUnderperform$25.00
4/16/2026
Pfizer Inc. stock logo
PFE
Pfizer
Initiated CoverageOutperform$33.00
4/14/2026
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
Initiated CoverageBuy$54.00
4/14/2026
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
Initiated CoverageBuy$54.00
(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B11.10N/AN/A$22.14 per share2.46
Ocugen, Inc. stock logo
OCGN
Ocugen
$4.41M111.69N/AN/A($0.04) per share-36.38
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.36$4.44 per share5.84$15.26 per share1.70
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
N/AN/AN/AN/A$4.86 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$8.15N/AN/AN/A-143.55%-26.64%-19.32%7/31/2026 (Estimated)
Ocugen, Inc. stock logo
OCGN
Ocugen
-$67.85M-$0.24N/AN/AN/A-1,192.18%-2,626.38%-138.99%7/30/2026 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$1.3119.809.08N/A11.83%19.44%8.41%N/A
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
-$119.95M-$2.01N/AN/AN/AN/A-41.17%-38.40%5/14/2026 (Estimated)

Latest OCGN, MRNA, PFE, and TYRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2026Q1 2026
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
-$0.60N/AN/AN/AN/AN/A
5/5/2026Q1 2026
Ocugen, Inc. stock logo
OCGN
Ocugen
-$0.05-$0.06-$0.01-$0.06$0.42 million$1.53 million
5/5/2026Q1 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.7220$0.75+$0.0280$0.47$13.84 billion$14.45 billion
5/1/2026Q1 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$3.02-$3.40-$0.38-$3.40$236.37 million$389.00 million
3/4/2026Q4 2025
Ocugen, Inc. stock logo
OCGN
Ocugen
-$0.06-$0.06N/A-$0.06$0.86 million($0.19) million
3/2/2026Q4 2025
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
-$0.54-$0.57-$0.03-$0.57N/AN/A
2/13/2026Q4 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.79-$2.11+$0.68-$2.11$611.14 million$678.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Ocugen, Inc. stock logo
OCGN
Ocugen
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.63%-13.20%131.30%16 Years
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
N/AN/AN/AN/AN/A

Latest OCGN, MRNA, PFE, and TYRA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/22/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.436.71%5/8/20265/8/20266/12/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Moderna, Inc. stock logo
MRNA
Moderna
0.08
2.41
2.35
Ocugen, Inc. stock logo
OCGN
Ocugen
8.04
1.06
1.06
Pfizer Inc. stock logo
PFE
Pfizer
0.67
1.25
0.94
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
N/A
14.67
14.67

Institutional Ownership

CompanyInstitutional Ownership
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Ocugen, Inc. stock logo
OCGN
Ocugen
10.27%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
84.14%

Insider Ownership

CompanyInsider Ownership
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
Ocugen, Inc. stock logo
OCGN
Ocugen
3.95%
Pfizer Inc. stock logo
PFE
Pfizer
0.62%
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
12.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700396.79 million353.93 millionOptionable
Ocugen, Inc. stock logo
OCGN
Ocugen
80338.52 million325.15 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.70 billion5.66 billionOptionable
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
2059.49 million52.05 millionOptionable

Recent News About These Companies

Tyra Bioscience, Inc
Tyra Bioscience (TYRA) Receives a Buy from Oppenheimer
Tyra Biosciences, Inc. ($TYRA) CEO 2025 Pay Revealed

New MarketBeat Followers Over Time

Media Sentiment Over Time

Moderna stock logo

Moderna NASDAQ:MRNA

$54.36 +1.48 (+2.80%)
As of 11:51 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Ocugen stock logo

Ocugen NASDAQ:OCGN

$1.46 -0.03 (-1.69%)
As of 11:51 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Pfizer stock logo

Pfizer NYSE:PFE

$25.96 +0.15 (+0.57%)
As of 11:51 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Tyra Biosciences stock logo

Tyra Biosciences NASDAQ:TYRA

$33.76 -0.25 (-0.73%)
As of 11:51 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.